Representativeness of clinical PET study participants with schizophrenia

A systematic review

So Kirino, Takefumi Suzuki, Hiroyoshi Takeuchi, Masaru Mimura, Hiroyuki Uchida

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

While positron emission tomography (PET) studies have provided invaluable data on antipsychotic effects, selection bias remains a serious concern. A systematic review of PET studies that measured dopamine D2 receptor blockade with antipsychotics was conducted to examine their inclusion/exclusion criteria, using PubMed, EMBASE, and ClinicalTrials.gov (last search, September 2016). PET studies were included if they measured D2 receptor occupancy in patients with schizophrenia and included introduction of antipsychotic treatment or antipsychotic regimen change in a systematic manner. Twenty-six studies were identified. Age limit was included in 13 studies; one study solely included geriatric patients while others targeted younger adults. Eleven, 6, and 3 studies specifically targeted clinically stable patients, patients with severe psychopathology, and antipsychotic-free patients, respectively. Nineteen and 18 studies excluded patients with physical comorbidity and substance abuse, respectively. As a result, the mean age of subjects ranged from 23 to 42 years when one study that targeted geriatric patients was excluded. Mean Positive and Negative Syndrome Scale total scores ranged from 54 to 95. No comparison active-drug or placebo arm was employed in 24 studies. Blind assessment of symptomatology was performed in 5 studies. In general, subjects participating in clinical PET studies were relatively young, presented with mild symptomatology, and were free from substance abuse or physical comorbidities. These characteristics need to be taken into account when clinical PET data are interpreted. On the other hand, it should also be noted that this study was only qualitative and conservative interpretation is necessary for possibility of subjective bias.

Original languageEnglish
Pages (from-to)72-79
Number of pages8
JournalJournal of Psychiatric Research
Volume88
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Positron-Emission Tomography
Schizophrenia
Antipsychotic Agents
Geriatrics
Substance-Related Disorders
Comorbidity
Dopamine D2 Receptors
Selection Bias
Systematic Review
Representativeness
Positron Emission Tomography
Psychopathology
PubMed
Young Adult
Placebos
Pharmaceutical Preparations

Keywords

  • Antipsychotic
  • Dopamine
  • Dopamine D receptor
  • Positron emission tomography
  • Schizophrenia

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Representativeness of clinical PET study participants with schizophrenia : A systematic review. / Kirino, So; Suzuki, Takefumi; Takeuchi, Hiroyoshi; Mimura, Masaru; Uchida, Hiroyuki.

In: Journal of Psychiatric Research, Vol. 88, 01.05.2017, p. 72-79.

Research output: Contribution to journalArticle

@article{b91b4a120edd483fa43027adcc9dd10f,
title = "Representativeness of clinical PET study participants with schizophrenia: A systematic review",
abstract = "While positron emission tomography (PET) studies have provided invaluable data on antipsychotic effects, selection bias remains a serious concern. A systematic review of PET studies that measured dopamine D2 receptor blockade with antipsychotics was conducted to examine their inclusion/exclusion criteria, using PubMed, EMBASE, and ClinicalTrials.gov (last search, September 2016). PET studies were included if they measured D2 receptor occupancy in patients with schizophrenia and included introduction of antipsychotic treatment or antipsychotic regimen change in a systematic manner. Twenty-six studies were identified. Age limit was included in 13 studies; one study solely included geriatric patients while others targeted younger adults. Eleven, 6, and 3 studies specifically targeted clinically stable patients, patients with severe psychopathology, and antipsychotic-free patients, respectively. Nineteen and 18 studies excluded patients with physical comorbidity and substance abuse, respectively. As a result, the mean age of subjects ranged from 23 to 42 years when one study that targeted geriatric patients was excluded. Mean Positive and Negative Syndrome Scale total scores ranged from 54 to 95. No comparison active-drug or placebo arm was employed in 24 studies. Blind assessment of symptomatology was performed in 5 studies. In general, subjects participating in clinical PET studies were relatively young, presented with mild symptomatology, and were free from substance abuse or physical comorbidities. These characteristics need to be taken into account when clinical PET data are interpreted. On the other hand, it should also be noted that this study was only qualitative and conservative interpretation is necessary for possibility of subjective bias.",
keywords = "Antipsychotic, Dopamine, Dopamine D receptor, Positron emission tomography, Schizophrenia",
author = "So Kirino and Takefumi Suzuki and Hiroyoshi Takeuchi and Masaru Mimura and Hiroyuki Uchida",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.jpsychires.2016.12.023",
language = "English",
volume = "88",
pages = "72--79",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Representativeness of clinical PET study participants with schizophrenia

T2 - A systematic review

AU - Kirino, So

AU - Suzuki, Takefumi

AU - Takeuchi, Hiroyoshi

AU - Mimura, Masaru

AU - Uchida, Hiroyuki

PY - 2017/5/1

Y1 - 2017/5/1

N2 - While positron emission tomography (PET) studies have provided invaluable data on antipsychotic effects, selection bias remains a serious concern. A systematic review of PET studies that measured dopamine D2 receptor blockade with antipsychotics was conducted to examine their inclusion/exclusion criteria, using PubMed, EMBASE, and ClinicalTrials.gov (last search, September 2016). PET studies were included if they measured D2 receptor occupancy in patients with schizophrenia and included introduction of antipsychotic treatment or antipsychotic regimen change in a systematic manner. Twenty-six studies were identified. Age limit was included in 13 studies; one study solely included geriatric patients while others targeted younger adults. Eleven, 6, and 3 studies specifically targeted clinically stable patients, patients with severe psychopathology, and antipsychotic-free patients, respectively. Nineteen and 18 studies excluded patients with physical comorbidity and substance abuse, respectively. As a result, the mean age of subjects ranged from 23 to 42 years when one study that targeted geriatric patients was excluded. Mean Positive and Negative Syndrome Scale total scores ranged from 54 to 95. No comparison active-drug or placebo arm was employed in 24 studies. Blind assessment of symptomatology was performed in 5 studies. In general, subjects participating in clinical PET studies were relatively young, presented with mild symptomatology, and were free from substance abuse or physical comorbidities. These characteristics need to be taken into account when clinical PET data are interpreted. On the other hand, it should also be noted that this study was only qualitative and conservative interpretation is necessary for possibility of subjective bias.

AB - While positron emission tomography (PET) studies have provided invaluable data on antipsychotic effects, selection bias remains a serious concern. A systematic review of PET studies that measured dopamine D2 receptor blockade with antipsychotics was conducted to examine their inclusion/exclusion criteria, using PubMed, EMBASE, and ClinicalTrials.gov (last search, September 2016). PET studies were included if they measured D2 receptor occupancy in patients with schizophrenia and included introduction of antipsychotic treatment or antipsychotic regimen change in a systematic manner. Twenty-six studies were identified. Age limit was included in 13 studies; one study solely included geriatric patients while others targeted younger adults. Eleven, 6, and 3 studies specifically targeted clinically stable patients, patients with severe psychopathology, and antipsychotic-free patients, respectively. Nineteen and 18 studies excluded patients with physical comorbidity and substance abuse, respectively. As a result, the mean age of subjects ranged from 23 to 42 years when one study that targeted geriatric patients was excluded. Mean Positive and Negative Syndrome Scale total scores ranged from 54 to 95. No comparison active-drug or placebo arm was employed in 24 studies. Blind assessment of symptomatology was performed in 5 studies. In general, subjects participating in clinical PET studies were relatively young, presented with mild symptomatology, and were free from substance abuse or physical comorbidities. These characteristics need to be taken into account when clinical PET data are interpreted. On the other hand, it should also be noted that this study was only qualitative and conservative interpretation is necessary for possibility of subjective bias.

KW - Antipsychotic

KW - Dopamine

KW - Dopamine D receptor

KW - Positron emission tomography

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85009089673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009089673&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2016.12.023

DO - 10.1016/j.jpsychires.2016.12.023

M3 - Article

VL - 88

SP - 72

EP - 79

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -